Table 1.
Characteristics of the study population (N =245)
| Age at diagnosis, y | 33 ± 16 (245) |
| Age at ustekinumab initiation, y | 42 ± 17 (233) |
| Disease duration, y | 9.12 ± 8.3 (233) |
| Sex | |
| Male | 105 (42.9) |
| Female | 140 (57.1) |
| Race | |
| NHW | 186 (75.9) |
| Not NHW | 49 (20.0) |
| Missing | 10 (4.1) |
| Smoker | |
| Current | 4 (1.6) |
| Past | 60 (24.5) |
| Never | 178 (72.7) |
| Unknown | 3 (1.2) |
| History of hospitalizations | |
| Yes | 89 (36.3) |
| No | 149 (60.8) |
| Unknown | 7 (2.9) |
| Body mass index, kg/m2 | 27.27 ± 8.26 (231) |
| Partial Mayo score at baseline | 5.0 (4-7) |
| History of extraintestinal manifestations | |
| Yes | 78 (31.8) |
| No | 162 (66.1) |
| Unknown | 5 (2.0) |
| Previous use of aminosalicylates | |
| Yes | 217 (88.6) |
| No | 20 (8.2) |
| Unknown | 8 (3.3) |
| Previous exposure to advanced treatment | |
| ≥1 anti-TNF agent only | 55 (22.5) |
| Vedolizumab only | 82 (33.4) |
| ≥1 anti-TNF agent and vedolizumab | 30 (12.2) |
| ≥1 anti-TNF agent, vedolizumab, and tofacitinib | 47 (19.2) |
| Previous use of methotrexate | |
| Yes | 49 (20.0) |
| No | 190 (77.6) |
| Unknown | 6 (2.4) |
| Previous use of thiopurine | |
| Yes | 115 (46.9) |
| No | 127 (51.8) |
| Unknown | 3 (1.2) |
| Disease extent | |
| E1 | 7 (2.9) |
| E2 | 45 (18.4) |
| E3 | 180 (73.5) |
| Unknown | 13 (5.3) |
| Albumin at baseline, g/dL | 4.01 ± 0.53 |
| Calprotectin at baseline, μg/mg | 699.00 (340.00-1380.00) |
| C-reactive protein, g/dL | 3.00 (0.90-10.70) |
| Use of steroids at baseline | |
| Yes | 130 (53.1) |
| No | 115 (46.9) |
| Concomitant use of immunomodulators at baseline | |
| Yes | 22 (9.0) |
| No | 223 (91.0) |
| Concomitant use of aminosalicylates at baseline | |
| Yes | 31 (12.7) |
| No | 214 (87.4) |
Values are mean ± SD (n), n (%), median (interquartile range), or mean ± SD.
Abbreviations: NHW, non-Hispanic White; TNF, tumor necrosis factor.